Effectiveness and Safety of Tofacitinib in Biologic-Naïve Elderly Patients with Ulcerative Colitis
January 2025
in “
Journal of Crohn s and Colitis
”
![Image of study](/images/research/f803ccb6-b5d2-4df4-b870-39c95228e864/medium/41281.jpg)
TLDR Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
This study evaluated the effectiveness and safety of tofacitinib in 35 biologic-naïve elderly patients (≥60 years) with moderate-to-severe ulcerative colitis at a tertiary care center in North India. The primary outcome, steroid-free clinical remission at both weeks 8 and 52, was achieved in 25.71% of patients. At week 8, clinical remission, steroid-free remission, and clinical response were observed in 51.42%, 42.85%, and 62.85% of patients, respectively. By week 52, these rates increased to 62.85% for both clinical remission and steroid-free remission, with a clinical response in 77.14% of patients. Common adverse events included hair loss (17.14%), sadness of mood (11.42%), and dyslipidemia (8.57%). The findings suggest that tofacitinib is a viable treatment option for this patient population.